Immunotherapy represents a fundamental shift in how doctors treat breast cancer, moving beyond directly attacking cancer cells to empowering the body's own immune system to recognize and destroy them. Unlike chemotherapy or targeted drugs that work directly on tumors, immunotherapy retrains immune cells to identify cancer hiding in plain sight. This approach is proving particularly valuable for triple-negative breast cancer (TNBC), an aggressive subtype that lacks hormone receptors and HER2 expression, making it harder to treat with conventional methods .

How Does Immunotherapy Actually Work Against Breast Cancer?

Cancer cells are master manipulators. They exploit the body's natural immune checkpoints, which normally prevent the immune system from attacking healthy tissue. By flipping these "brakes" on, cancer cells essentially hide from immune detection. Immunotherapy drugs work by releasing those brakes, allowing immune cells to attack malignant cells more effectively .

The most commonly used immunotherapy drug for breast cancer is pembrolizumab, a checkpoint inhibitor that targets the PD-1 receptor on immune cells. By blocking this receptor, the medicine allows T cells, which are specialized immune warriors, to recognize and attack cancer cells more effectively. Another drug used in selected cases is atezolizumab, which targets the PD-L1 protein on both cancer cells and immune cells .

What Are the Different Types of Immunotherapy Being Used?

• Checkpoint Inhibitors: These drugs block the "brakes" that cancer cells use to hide from the immune system, freeing immune cells to attack tumors more aggressively.
• Immunomodulators: These medications boost the overall activity of the immune system, enhancing its natural cancer-fighting abilities.
• Cell-Based Therapies: Immune cells are enhanced or engineered outside the body, then infused back to target cancer more powerfully.
• Cancer Vaccines: These help the body recognize cancer-specific markers and develop long-term immune defense against recurrence.

These treatments have already improved outcomes in melanoma, lung cancer, kidney cancer, and many other cancer types .

How Is Immunotherapy Being Used at Different Breast Cancer Stages?

The timing and approach of immunotherapy varies depending on how advanced the cancer is. For patients with high-risk early-stage TNBC, immunotherapy is now combined with chemotherapy before surgery. This approach increases the chance of completely eliminating cancer in the breast and lymph nodes, and may reduce the risk of recurrence in the future. When the tumor is large or has spread to nearby lymph nodes but not distant organs, immunotherapy plus chemotherapy can shrink the cancer, making surgery more successful and improving long-term outcomes .

For patients with metastatic TNBC (cancer that has spread to distant sites), immunotherapy has shown meaningful benefit, particularly in patients whose tumors express PD-L1, an immune checkpoint marker. In some selected patients, tumors shrink significantly, making ongoing treatment more manageable .

What Are the Key Benefits Over Traditional Chemotherapy?

• Personalized Treatment: Immunotherapy can be tailored based on cancer biology and specific immune markers, allowing doctors to match patients with the treatments most likely to work for them.
• Better Tolerance: Many patients experience fewer side effects with immunotherapy compared to traditional chemotherapy, which can cause severe nausea, hair loss, and organ damage.
• Long-Lasting Immune Memory: Immunotherapy trains the immune system to remember cancer cells, helping keep cancer away even after treatment stops, reducing the risk of relapse.

What Side Effects Should Patients Expect?

Because immunotherapy activates the immune system, the most common reactions come from the immune system attacking healthy tissues, called immune-related adverse events (irAEs). These differ significantly from chemotherapy side effects .

Common side effects include skin reactions such as rash, itching, dryness, or changes in skin color, which are usually mild and manageable with creams or medicines. Fatigue is also common, ranging from mild tiredness to more significant weakness. Some patients experience gastrointestinal symptoms like diarrhea or bowel inflammation (colitis). More serious but less common effects include inflammation of hormone glands like the thyroid, adrenal glands, or pituitary gland, which can lead to hormonal imbalance and may require hormone replacement therapy. Lung inflammation (pneumonitis) can cause cough, breathlessness, or chest discomfort and needs prompt medical attention. Liver inflammation (hepatitis) is usually detected by blood tests before symptoms appear .

The good news is that most immune-related adverse events respond very well to timely treatment, especially with corticosteroids or temporary pause of immunotherapy. During treatment, patients are closely followed with regular check-ups and blood tests. Any new symptom, even if small, should be reported early so doctors can act quickly and prevent complications .

What Do Landmark Clinical Trials Show?

The introduction of immunotherapy in breast cancer has been driven by major clinical trials. The KEYNOTE-522 trial was a breakthrough in early-stage disease, showing that adding pembrolizumab to neoadjuvant chemotherapy (chemotherapy given before surgery) significantly increased the rate of pathological complete response, meaning no cancer cells remained after treatment. This improvement also led to better event-free survival, meaning patients lived longer without their cancer returning or progressing. These results led to global approval for high-risk early-stage TNBC .

In metastatic settings, the KEYNOTE-355 trial demonstrated that pembrolizumab combined with chemotherapy offered meaningful survival benefits for patients whose tumors expressed PD-L1 .

What's Next for Immunotherapy in Breast Cancer?

Research is rapidly progressing to expand immunotherapy beyond TNBC to other breast cancer subtypes, identify which patients benefit the most from specific treatments, and improve combinations with targeted therapy, hormone therapy, and radiation. Currently, immunotherapy is not yet appropriate for all breast cancer patients, but it is becoming a strong and growing pillar of modern cancer care .

The shift from only attacking cancer to empowering the immune system to stay vigilant represents a major evolution in how doctors approach breast cancer treatment. For patients with aggressive forms of the disease, this new era of immunotherapy offers genuine hope where options were previously limited.